Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)

Recruiting

Phase 2

Lenacapavir & F/TDFStudy of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)

Sponsor:

Gilead Sciences

Code:

NCT06101342

Conditions

Pre-Exposure Prophylaxis of HIV Infection

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

Lenacapavir Injection

Lenacapavir Tablet

Emtricitabine/tenofovir disoproxil fumarate (F/TDF)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by Gilead Sciences on 2025-05-15.